Loading...
•
Dec 31, 2021
Corvus Pharmaceuticals Q4 2021 Earnings Report
Provided business update and reported financial results for the fourth quarter and year ended December 31, 2021
Key Takeaways
Corvus Pharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2021, with research and development expenses totaling $4.8 million. As of December 31, 2021, the company's cash, cash equivalents, and marketable securities amounted to $69.5 million.
Advanced three clinical programs for product candidates targeting CD73, the adenosine 2A receptor, and ITK.
Initiated mid-stage clinical trials in front-line treatment of lung cancer and renal cell cancer.
Partnership with Angel Pharmaceuticals has expanded clinical development of CPI-818 for T cell lymphomas into China.
Company had cash, cash equivalents and marketable securities totaling $69.5 million as of December 31, 2021.
Forward Guidance
Corvus expects full year 2022 net cash used in operating activities to be between $34 million and $36 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...